U.S., March 24 -- ClinicalTrials.gov registry received information related to the study (NCT07488975) titled 'Developing Microbial Therapy for MASLD: From Mechanism to Clinical Validation' on Feb. 05, 2025.
Brief Summary: Metabolic dysfunction-associated steatotic liver disease (MASLD), redefined in 2020, is an improved diagnostic standard evolved from non-alcoholic fatty liver disease (NAFLD), emphasizing the correlation between hepatic steatosis and metabolic dysfunction. Compared to NAFLD, which relies on exclusion-based diagnosis, MASLD criteria enhance population homogeneity in studies and accommodate patients with coexisting liver diseases, thereby improving the efficiency and relevance of drug development. MASLD affects approximatel...